07.24.12
11. Becton Dickinson & Co.
$ 7.8 Billion
KEY EXECUTIVES:
Edward J. Ludwig, Chairman
Vincent A. Forlenza, President and CEO
David V. Elkins, Exec. VP & Chief Financial Officer & Treasurer
Pierre Boisier, Sr. VP, Quality
Scott P. Bruder, M.D., Ph.D., Sr. VP & Chief Technology Officer
David T. Durack, Sr. VP, Corporate Medical Affairs
NO. OF EMPLOYEES: 29,400
GLOBAL HEADQUARTERS: Franklin Lakes, N.J.
Becton Dickinson (BD) and Co.’s Medical, Diagnostics, and Biosciences divisions brought the company a total of $7.8 billion in sales, up 6.2 percent, for fiscal year 2011, (ended Sept. 30). Despite an uptick in sales for the year, net earnings were relatively flat. The company’s profit totaled $1.27 billion, down slightly from $1.31 billion in 2010. Almost $4.5 billion in sales were from international markets.
Sales for BD Medical (which includes products for anesthesia, infusion therapy, injection, sharps disposal and surgery; diabetes care; and surgical systems) increased 5.6 percent to $4 billion. BD Diagnostics (diagnostics and prenatal systems recorded earnings of just under $2.5 billion, an increase of 7 percent. BD BioSciences (cell analysis and discovery labware) grew sales by 6.7 percent to $1.3 billion.
BD made two strategic acquisitions during the fiscal year. In March it acquired Accuri Cytometers Inc., a company dedicated to manufacturing personal flow cytometers for researchers. Cytometry is the science of measuring and examining cells. The company was folded into BD’s Biosciences division, and Accuri’s signature product now is known as the BD Accuri flow cytometer, and has a variety of applications even outside the medical space such as environmental studies.
In September just before the close of the fiscal year, BD closed the acquisition of Carmel Pharma AB, a Swedish company that manufactures the BD PhaSeal system. The PhaSeal system is a closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. Carmel and the technology it brought with it were added to enable BD’s Medical Surgical Systems unit to “enter early stage market with significant long-term growth potential,” according to a letter to shareholders penned by CEO Vincent Forlenza (who became chief executive in June 2011 after successfully holding key leadership positions at the company throughout the years) and Chairman Edward Ludwig.
FY2011 also saw the release of a few new products.
The Vacutainer Rapid Serum Tube was released in October 2010. The blood collection device is designed to aid acute healthcare facilities in rapidly analyzing blood serum for patient diagnosis, and has 510(k) clearance from the U.S. Food and Drug Administration. The device is claimed to facilitate a five-minute clotting time and as little as three minutes of centrifugation, saving an alleged 32 minutes of laboratory time.
Some other notable products releases include: The BD AutoShield Duo Pen Needle, a next-generation product designed to protect healthcare workers from needlestick injuries and blood exposure at both the front and back ends of the needle launched by the Diabetes Care unit; The BD MAX System, a fully automated system designed for a range of molecular testing released by the company’s Diagnostic Systems unit; and the BD FACSVerse Flow Cytometer, introduced by the Cell Analysis unit. Overall, new products accounted for 8 percent of total revenues in FY2011.
The focus of FY2011 was research and development with an eye on the future, rather than contemporary product releases per se. FY2012 already is promising to be a much busier year in terms of technology, having already seen the release of three new products thus far, according to the company’s leadership.
“Our current product pipeline is the most robust in company history,” Forlenza and Ludwig told shareholders in the company’s annual report. “We have plans to launch more innovative products across our segments through fiscal years 2012 and 2013.” Future technologies are set to target diabetes, cancer, chronic and infectious diseases, and HIV/AIDS among other healthcare needs.
Becton Dickinson was among the companies affected by the Tohuku earthquake and tsunami of March 11, 2011, in Japan. The company’s Fukushima manufacturing plant closed down temporarily, while its Tokyo office was undamaged. No BD employees were injured or killed. The company donated $325,000 to relief efforts, being heavily invested in the Japanese device web. BD also matched donations from employees globally to the American Red Cross and the U.S. Fund for UNICEF.
BD’s company ethic of social responsibility did not end with Japan. During the fiscal year, BD sent human and monetary resources to Haiti to continue efforts one year after the earthquake of 2010; to Australia and New Zealand to help in flood recovery efforts; and to the Red Cross to aid in recovery following the Mississippi River flooding in the United States. Charitable donations also were made to help the victims of Hurricane Irene and the floods in the Northeast region.
$ 7.8 Billion
KEY EXECUTIVES:
Edward J. Ludwig, Chairman
Vincent A. Forlenza, President and CEO
David V. Elkins, Exec. VP & Chief Financial Officer & Treasurer
Pierre Boisier, Sr. VP, Quality
Scott P. Bruder, M.D., Ph.D., Sr. VP & Chief Technology Officer
David T. Durack, Sr. VP, Corporate Medical Affairs
NO. OF EMPLOYEES: 29,400
GLOBAL HEADQUARTERS: Franklin Lakes, N.J.
Becton Dickinson (BD) and Co.’s Medical, Diagnostics, and Biosciences divisions brought the company a total of $7.8 billion in sales, up 6.2 percent, for fiscal year 2011, (ended Sept. 30). Despite an uptick in sales for the year, net earnings were relatively flat. The company’s profit totaled $1.27 billion, down slightly from $1.31 billion in 2010. Almost $4.5 billion in sales were from international markets.
Sales for BD Medical (which includes products for anesthesia, infusion therapy, injection, sharps disposal and surgery; diabetes care; and surgical systems) increased 5.6 percent to $4 billion. BD Diagnostics (diagnostics and prenatal systems recorded earnings of just under $2.5 billion, an increase of 7 percent. BD BioSciences (cell analysis and discovery labware) grew sales by 6.7 percent to $1.3 billion.
BD made two strategic acquisitions during the fiscal year. In March it acquired Accuri Cytometers Inc., a company dedicated to manufacturing personal flow cytometers for researchers. Cytometry is the science of measuring and examining cells. The company was folded into BD’s Biosciences division, and Accuri’s signature product now is known as the BD Accuri flow cytometer, and has a variety of applications even outside the medical space such as environmental studies.
In September just before the close of the fiscal year, BD closed the acquisition of Carmel Pharma AB, a Swedish company that manufactures the BD PhaSeal system. The PhaSeal system is a closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. Carmel and the technology it brought with it were added to enable BD’s Medical Surgical Systems unit to “enter early stage market with significant long-term growth potential,” according to a letter to shareholders penned by CEO Vincent Forlenza (who became chief executive in June 2011 after successfully holding key leadership positions at the company throughout the years) and Chairman Edward Ludwig.
FY2011 also saw the release of a few new products.
The Vacutainer Rapid Serum Tube was released in October 2010. The blood collection device is designed to aid acute healthcare facilities in rapidly analyzing blood serum for patient diagnosis, and has 510(k) clearance from the U.S. Food and Drug Administration. The device is claimed to facilitate a five-minute clotting time and as little as three minutes of centrifugation, saving an alleged 32 minutes of laboratory time.
Some other notable products releases include: The BD AutoShield Duo Pen Needle, a next-generation product designed to protect healthcare workers from needlestick injuries and blood exposure at both the front and back ends of the needle launched by the Diabetes Care unit; The BD MAX System, a fully automated system designed for a range of molecular testing released by the company’s Diagnostic Systems unit; and the BD FACSVerse Flow Cytometer, introduced by the Cell Analysis unit. Overall, new products accounted for 8 percent of total revenues in FY2011.
The focus of FY2011 was research and development with an eye on the future, rather than contemporary product releases per se. FY2012 already is promising to be a much busier year in terms of technology, having already seen the release of three new products thus far, according to the company’s leadership.
“Our current product pipeline is the most robust in company history,” Forlenza and Ludwig told shareholders in the company’s annual report. “We have plans to launch more innovative products across our segments through fiscal years 2012 and 2013.” Future technologies are set to target diabetes, cancer, chronic and infectious diseases, and HIV/AIDS among other healthcare needs.
Becton Dickinson was among the companies affected by the Tohuku earthquake and tsunami of March 11, 2011, in Japan. The company’s Fukushima manufacturing plant closed down temporarily, while its Tokyo office was undamaged. No BD employees were injured or killed. The company donated $325,000 to relief efforts, being heavily invested in the Japanese device web. BD also matched donations from employees globally to the American Red Cross and the U.S. Fund for UNICEF.
BD’s company ethic of social responsibility did not end with Japan. During the fiscal year, BD sent human and monetary resources to Haiti to continue efforts one year after the earthquake of 2010; to Australia and New Zealand to help in flood recovery efforts; and to the Red Cross to aid in recovery following the Mississippi River flooding in the United States. Charitable donations also were made to help the victims of Hurricane Irene and the floods in the Northeast region.
| < Previous - Stryker | Boston Scientific - Next > |
